Sugi Predict

Sugi Predict / Compounds / SCHEMBL2138193

SCHEMBL2138193

SCHEMBL2138193

Cc1ccc(S(=O)(=O)n2ccc3cc(C=O)ccc32)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 5/20 0.54
▸ CYP2A6 P11509 1/20 0.51
▸ HDAC1 Q13547 8/20 0.50
▸ HDAC6 Q9UBN7 8/20 0.50
▸ HDAC3 O15379 7/20 0.50
▸ HDAC8 Q9BY41 7/20 0.50
▸ HDAC2 Q92769 6/20 0.50
▸ HDAC10 Q969S8 6/20 0.50
▸ HDAC4 P56524 5/20 0.50
▸ HDAC7 Q8WUI4 5/20 0.50
▸ HDAC11 Q96DB2 5/20 0.50
▸ HDAC9 Q9UKV0 5/20 0.50
▸ HDAC5 Q9UQL6 5/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ POLB P06746 1/20 0.48
▸ PPARG P37231 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ UBE2N P61088 1/20 0.46
▸ RAPGEF4 Q8WZA2 2/20 0.45
▸ HTT P42858 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30285445 1.00 HTR6 (0.54) HTR6CYP2A6HDAC1HDAC6HDAC3
SCHEMBL2134757 0.89 CYP2A6 (0.51) HTR6CYP2A6HDAC1HDAC6HDAC3
SCHEMBL29565687 0.88 HTR6 (0.53) HTR6HDAC1HDAC6HDAC3HDAC8
SCHEMBL28264249 0.88 HTR6 (0.53) HTR6HDAC1HDAC6HDAC3HDAC8
SCHEMBL29963796 0.86 HTR6 (0.65) HTR6CYP2A6HDAC1HDAC6HDAC3
SCHEMBL723576 0.86 HTR6 (0.65) HTR6CYP2A6HDAC1HDAC6HDAC3
SCHEMBL1894102 0.85 HTR6 (0.61) HTR6HDAC1HDAC6L3MBTL1POLB
SCHEMBL32691803 0.84 HDAC1 (0.52) HTR6HDAC1HDAC6HDAC3HDAC8
SCHEMBL26604326 0.84 HDAC1 (0.52) HTR6HDAC1HDAC6HDAC3HDAC8
SCHEMBL2136864 0.82 HDAC1 (0.64) HTR6HDAC1HDAC6HDAC3HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454502-B2 Synthesis of deuterated aldehydes ARIZONA BOARD OF REGENTS ON BEHALF OF ATHE UNIVERSITY OF ARIZONA (US) 2025-10-28 — — US disclosed
US-20220356139-A1 SYNTHESIS OF DEUTERATED ALDEHYDES ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2022-11-10 — — US disclosed
WO-2021045879-A1 SYNTHESIS OF DEUTERATED ALDEHYDES ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2021-03-11 — — WO disclosed
EP-3632899-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RaQualia Pharma Inc. (JP) 2020-04-08 — — EP disclosed
EP-2435407-B1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC (JP) 2019-12-25 — — EP disclosed
CN-108658869-A Compound with anti-tumor activity and preparation method thereof and the purposes in pharmacy 复旦大学 2018-10-16 — — CN disclosed
US-9522140-B2 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers RAQUALIA PHARMA INC. (JP) 2016-12-20 — — US disclosed
US-20150322052-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC (JP) 2015-11-12 — — US disclosed
US-9101616-B2 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers RAQUALIA PHARMA INC. (JP) 2015-08-11 — — US disclosed
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 — — US disclosed
WO-2010137351-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC. (JP) 2010-12-02 — — WO disclosed
US-6613942-B1 Nonpeptide; 4-hydroxy benzoic acid hydrazides NOVO NORDISK A/S (DK) 2003-09-02 — — US disclosed
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 — — US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 — — US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 — — WO disclosed
EP-0994848-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-04-26 — — EP disclosed
WO-1999001423-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 1999-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 HTR6 3407/4885CYP2A6 3788/4885HDAC1 220/4885
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1H HTR6 1715/4885CYP2A6 1994/4885HDAC1 217/4885
US-12454502-B2 Synthesis of deuterated aldehydes ADH1C, ADH1A, CBR1 HTR6 1481/4885CYP2A6 704/4885HDAC1 1185/4885
US-20150322052-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1H HTR6 1699/4885CYP2A6 2006/4885HDAC1 223/4885
US-20220356139-A1 SYNTHESIS OF DEUTERATED ALDEHYDES ADH1C, ADH1A, CBR1 HTR6 1481/4885CYP2A6 704/4885HDAC1 1185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.